Felbamate: Consensus of current clinical experience

John M. Pellock, Edward Faught, Ilo E. Leppik, Shlomo Shinnar, Mary L. Zupanc

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

An expert panel convened to evaluate data and review current clinical practices regarding the novel antiepileptic drug (AED) felbamate. Felbamate has demonstrated efficacy against a variety of refractory seizures types, including seizures associated with Lennox-Gastaut syndrome, but postmarketing experience revealed serious idiosyncratic adverse effects that were not observed during clinical trials. Although felbamate is not indicated as first-line antiepileptic therapy, its utility in treating seizures that are refractory to other AEDs is undisputed, as shown by the number of patients who continue to use it. New exposures to felbamate number approximately 3200-4200 patients annually, and it is estimated that over the past 10 years, approximately 35,000 new starts have occurred. Recommendations by the American Academy of Neurology and a review of felbamate literature were evaluated in conjunction with the clinical experience of the expert panel to determine current medical opinion and practice regarding felbamate. The past 10 years of clinical experience have demonstrated that when used in accordance with existing recommendations and close clinical monitoring, felbamate is an effective treatment for some patients with seizures refractory to other AEDs. This review of clinical data and discussion of the current understanding of the risk:benefit of felbamate therapy supports its use as an important therapeutic option for some patients with refractory epilepsy.

Original languageEnglish (US)
Pages (from-to)89-101
Number of pages13
JournalEpilepsy Research
Volume71
Issue number2-3
DOIs
StatePublished - Oct 2006

Fingerprint

felbamate
Seizures
Anticonvulsants
Therapeutics

Keywords

  • Antiepileptic drugs
  • Aplastic anemia
  • Felbamate
  • Hepatic toxicity
  • Lennox-Gastaut syndrome
  • Refractory epilepsy

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neurology

Cite this

Pellock, J. M., Faught, E., Leppik, I. E., Shinnar, S., & Zupanc, M. L. (2006). Felbamate: Consensus of current clinical experience. Epilepsy Research, 71(2-3), 89-101. https://doi.org/10.1016/j.eplepsyres.2006.06.020

Felbamate : Consensus of current clinical experience. / Pellock, John M.; Faught, Edward; Leppik, Ilo E.; Shinnar, Shlomo; Zupanc, Mary L.

In: Epilepsy Research, Vol. 71, No. 2-3, 10.2006, p. 89-101.

Research output: Contribution to journalArticle

Pellock, JM, Faught, E, Leppik, IE, Shinnar, S & Zupanc, ML 2006, 'Felbamate: Consensus of current clinical experience', Epilepsy Research, vol. 71, no. 2-3, pp. 89-101. https://doi.org/10.1016/j.eplepsyres.2006.06.020
Pellock, John M. ; Faught, Edward ; Leppik, Ilo E. ; Shinnar, Shlomo ; Zupanc, Mary L. / Felbamate : Consensus of current clinical experience. In: Epilepsy Research. 2006 ; Vol. 71, No. 2-3. pp. 89-101.
@article{1106d70daa4448169207a07e08a609fd,
title = "Felbamate: Consensus of current clinical experience",
abstract = "An expert panel convened to evaluate data and review current clinical practices regarding the novel antiepileptic drug (AED) felbamate. Felbamate has demonstrated efficacy against a variety of refractory seizures types, including seizures associated with Lennox-Gastaut syndrome, but postmarketing experience revealed serious idiosyncratic adverse effects that were not observed during clinical trials. Although felbamate is not indicated as first-line antiepileptic therapy, its utility in treating seizures that are refractory to other AEDs is undisputed, as shown by the number of patients who continue to use it. New exposures to felbamate number approximately 3200-4200 patients annually, and it is estimated that over the past 10 years, approximately 35,000 new starts have occurred. Recommendations by the American Academy of Neurology and a review of felbamate literature were evaluated in conjunction with the clinical experience of the expert panel to determine current medical opinion and practice regarding felbamate. The past 10 years of clinical experience have demonstrated that when used in accordance with existing recommendations and close clinical monitoring, felbamate is an effective treatment for some patients with seizures refractory to other AEDs. This review of clinical data and discussion of the current understanding of the risk:benefit of felbamate therapy supports its use as an important therapeutic option for some patients with refractory epilepsy.",
keywords = "Antiepileptic drugs, Aplastic anemia, Felbamate, Hepatic toxicity, Lennox-Gastaut syndrome, Refractory epilepsy",
author = "Pellock, {John M.} and Edward Faught and Leppik, {Ilo E.} and Shlomo Shinnar and Zupanc, {Mary L.}",
year = "2006",
month = "10",
doi = "10.1016/j.eplepsyres.2006.06.020",
language = "English (US)",
volume = "71",
pages = "89--101",
journal = "Epilepsy Research",
issn = "0920-1211",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Felbamate

T2 - Consensus of current clinical experience

AU - Pellock, John M.

AU - Faught, Edward

AU - Leppik, Ilo E.

AU - Shinnar, Shlomo

AU - Zupanc, Mary L.

PY - 2006/10

Y1 - 2006/10

N2 - An expert panel convened to evaluate data and review current clinical practices regarding the novel antiepileptic drug (AED) felbamate. Felbamate has demonstrated efficacy against a variety of refractory seizures types, including seizures associated with Lennox-Gastaut syndrome, but postmarketing experience revealed serious idiosyncratic adverse effects that were not observed during clinical trials. Although felbamate is not indicated as first-line antiepileptic therapy, its utility in treating seizures that are refractory to other AEDs is undisputed, as shown by the number of patients who continue to use it. New exposures to felbamate number approximately 3200-4200 patients annually, and it is estimated that over the past 10 years, approximately 35,000 new starts have occurred. Recommendations by the American Academy of Neurology and a review of felbamate literature were evaluated in conjunction with the clinical experience of the expert panel to determine current medical opinion and practice regarding felbamate. The past 10 years of clinical experience have demonstrated that when used in accordance with existing recommendations and close clinical monitoring, felbamate is an effective treatment for some patients with seizures refractory to other AEDs. This review of clinical data and discussion of the current understanding of the risk:benefit of felbamate therapy supports its use as an important therapeutic option for some patients with refractory epilepsy.

AB - An expert panel convened to evaluate data and review current clinical practices regarding the novel antiepileptic drug (AED) felbamate. Felbamate has demonstrated efficacy against a variety of refractory seizures types, including seizures associated with Lennox-Gastaut syndrome, but postmarketing experience revealed serious idiosyncratic adverse effects that were not observed during clinical trials. Although felbamate is not indicated as first-line antiepileptic therapy, its utility in treating seizures that are refractory to other AEDs is undisputed, as shown by the number of patients who continue to use it. New exposures to felbamate number approximately 3200-4200 patients annually, and it is estimated that over the past 10 years, approximately 35,000 new starts have occurred. Recommendations by the American Academy of Neurology and a review of felbamate literature were evaluated in conjunction with the clinical experience of the expert panel to determine current medical opinion and practice regarding felbamate. The past 10 years of clinical experience have demonstrated that when used in accordance with existing recommendations and close clinical monitoring, felbamate is an effective treatment for some patients with seizures refractory to other AEDs. This review of clinical data and discussion of the current understanding of the risk:benefit of felbamate therapy supports its use as an important therapeutic option for some patients with refractory epilepsy.

KW - Antiepileptic drugs

KW - Aplastic anemia

KW - Felbamate

KW - Hepatic toxicity

KW - Lennox-Gastaut syndrome

KW - Refractory epilepsy

UR - http://www.scopus.com/inward/record.url?scp=33748764381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748764381&partnerID=8YFLogxK

U2 - 10.1016/j.eplepsyres.2006.06.020

DO - 10.1016/j.eplepsyres.2006.06.020

M3 - Article

C2 - 16889941

AN - SCOPUS:33748764381

VL - 71

SP - 89

EP - 101

JO - Epilepsy Research

JF - Epilepsy Research

SN - 0920-1211

IS - 2-3

ER -